Compare EYPT & GSRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EYPT | GSRF |
|---|---|---|
| Founded | 1987 | 2023 |
| Country | United States | United States |
| Employees | 214 | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.1M | 298.8M |
| IPO Year | 2005 | 2025 |
| Metric | EYPT | GSRF |
|---|---|---|
| Price | $3.33 | $10.23 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $31.80 | N/A |
| AVG Volume (30 Days) | ★ 3.3M | 12.2K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,539,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3,115.57 | N/A |
| P/E Ratio | ★ N/A | $184.52 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.42 | $9.96 |
| 52 Week High | $19.11 | $10.24 |
| Indicator | EYPT | GSRF |
|---|---|---|
| Relative Strength Index (RSI) | 28.88 | 70.85 |
| Support Level | N/A | $10.15 |
| Resistance Level | $14.72 | N/A |
| Average True Range (ATR) | 0.32 | 0.00 |
| MACD | 0.21 | 0.00 |
| Stochastic Oscillator | 5.02 | 87.50 |
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
GSR IV Acquisition Corp is a blank check company.